-
Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk of preeclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, ElKhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2014;44:402-10. pdf -
Maternal and foetal angiogenic imbalance in congenital heart defects.
Llurba E, Sánchez O, Ferrer Q, Nicolaides KH, Ruíz A, Domínguez C, Sánchez-de-Toledo J, García-García B, Soro G, Arévalo S, Goya M, Suy A, Pérez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L.
Eur Heart J 2014;35:701-7. -
Maternal thyroid function at gestational weeks 11-13 in twin pregnancies.
Ashoor G, Muto O, Poon LC, Muhaisen M, Nicolaides KH.
Thyroid 2013;23:1165-71. -
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013;33:149-55. -
Maternal thyroid function at eleven to thirteen weeks of gestation and subsequent delivery of small for gestational age neonates.
Karagiannis G, Ashoor G, Maiz N, Jawdat F, Nicolaides KH.
Thyroid 2011;21:1127-31. -
Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18.
Ashoor G, Maiz N, Cuckle H, Jawdat F, Nicolaides KH.
Prenat Diagn 2011;31:33-7. -
Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery.
Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
Obstet Gynecol 2011;117:293-8. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:680-7. -
Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of preeclampsia.
Ashoor G, Maiz N, Rotas M, Kametas NA, Nicolaides KH.
Prenat Diagn 2010;30:1032-8. -
Maternal thyroid function at 11-13 Weeks of gestation in women with hypothyroidism treated by thyroxine.
Ashoor G, Rotas M, Maiz N, Kametas NA, Nicolaides KH.
Fetal Diagn Ther 2010;28:22-27. -
Maternal thyroid function at 11-13 weeks of gestation.
Ashoor G, Kametas NA, Akolekar R, Guisado J, Nicolaides KH.
Fetal Diagn Ther 2010;27:156-63. -
Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death.
Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
Thyroid 2010;20:989-93. -
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH.
Prenat Diagn 2010;30:191-7. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9. -
Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction.
Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH.
Am J Obstet Gynecol 2006;195:1668-73. -
Maternal thyroid function in multifetal pregnancies before and after fetal reduction.
Ogueh O, Hawkins AP, Abbas A, Carter GD, Nicolaides KH, Johnson MR.
J Endocrin 2000;164:7-11.